Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy

International Journal of Gynecological Cancer

Volumn 15, Issue 1, 2005, Pages 45-49

  Kikuchi, A ^a   Sakamoto, Hideki ^a   Yamamoto, T ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Paclitaxel; Recurrent ovarian cancer; Weekly carboplatin

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; PACLITAXEL; PLATINUM DERIVATIVE; RANITIDINE; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CASE-CONTROL STUDIES; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 13244265544     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2005.15006.x     Document Type: Article

References (8)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Eisenhauer EA, Vermerken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-8.
3. Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001;83:128-34.
4. Dizon DS, Hensley ML, Poynor EA et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002;20: 1238-47.
5. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998;16:1494-7.
6. Kurihara M, Sakamoto H, Ohta Y et al. Patient compliance and the quality of life are well maintained in weekly paclitaxel and carboplatin therapy for advanced gynecologic cancers in Japanese women. Gan Kagaku Ryoho 2001;28:55-61.
7. Wu CH, Yang CH, Lee JN, Hsu SC, Tsai EM. Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. Int J Gynecol Cancer 2001;11:295-9.
8. Ohtani K, Sakamoto H, Masaoka N et al. A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration. Gynecol Oncol 2000;79:515-8.